Shots:

• PharmEnable to receive an up front and will be eligible to receive development and commercial milestones. Denali will be responsible for the further lead optimization, development, and commercialization of the products
• The collaboration will combine PharmEnable’ AI drug discovery platform with Denali's expertise in delivery across the BBB and neurodegeneration to identify therapeutically relevant small molecule chemical matter against challenging targets
• PharmEnable's drug discovery platform is a potent engine for creating novel chemical entities against a difficult target. Additionally, joint research programs are to be initiated over the next 2yrs. against multiple undisclosed targets

Ref: Denali  | Image: Denali